EP1212422B1
(en)
*
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
NZ520392A
(en)
|
2000-02-10 |
2005-04-29 |
Abbott Lab |
Antibodies that bind human interleukin-18 and methods of making and using
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
HUP0302525A2
(hu)
|
2001-01-05 |
2003-10-28 |
Abgenix, Inc. |
Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
|
ES2321065T3
(es)
|
2001-04-26 |
2009-06-02 |
Biogen Idec Ma Inc. |
Anticuerpos bloqueantes de cripto y usos de los mismos.
|
JP2005519580A
(ja)
|
2001-05-16 |
2005-07-07 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
非ヒト動物由来のヒト抗肺炎球菌抗体
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
CA2451955C
(en)
*
|
2001-06-26 |
2015-09-29 |
Abgenix, Inc. |
Antibodies to opgl
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
ATE435239T1
(de)
|
2002-03-29 |
2009-07-15 |
Schering Corp |
Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
|
NZ536420A
(en)
*
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
JP2006500931A
(ja)
*
|
2002-09-30 |
2006-01-12 |
ファイザー・プロダクツ・インク |
高レベルのヒト配列抗体を産生するハイブリドーマ
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
JP2007528721A
(ja)
*
|
2003-08-14 |
2007-10-18 |
ダイアックス コーポレイション |
エンドセリアーゼ−2リガンド
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
DK2177537T3
(da)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antistoffer til MAdCAM
|
RU2346702C2
(ru)
*
|
2004-03-26 |
2009-02-20 |
Пфайзер Продактс Инк. |
Применение антител к ctla-4
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
EP1791868B1
(en)
|
2004-07-01 |
2011-02-23 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
EP1802341A1
(en)
|
2004-07-16 |
2007-07-04 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
EP2899277A1
(en)
*
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
WO2006096490A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
EP1868644A1
(en)
*
|
2005-03-23 |
2007-12-26 |
Pfizer Products Incorporated |
Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
MX2007013217A
(es)
|
2005-04-25 |
2008-03-11 |
Pfizer |
Anticuerpos contra miostatina.
|
AP2552A
(en)
|
2005-04-26 |
2013-01-08 |
Pfizer |
P-cadherin antibodies
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質viモノクローナル抗体
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
SI1907000T2
(sl)
|
2005-06-08 |
2020-07-31 |
Dana-Farber Cancer Institute |
Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti
|
SG163583A1
(en)
*
|
2005-07-07 |
2010-08-30 |
Coley Pharm Group Inc |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AU2006283532B2
(en)
|
2005-08-19 |
2012-04-26 |
Abbvie Inc. |
Dual variable domain immunoglobin and uses thereof
|
PL2960253T3
(pl)
|
2005-09-07 |
2018-11-30 |
Amgen Fremont Inc. |
Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
JP2009514977A
(ja)
|
2005-11-08 |
2009-04-09 |
メダレックス インコーポレーティッド |
免疫刺激性治療用抗体による治療に付随した腸炎に対するTNF−α遮断剤処置法
|
BRPI0619249A2
(pt)
|
2005-11-30 |
2011-09-20 |
Abbott Lab |
anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
|
CN101506236B
(zh)
|
2005-11-30 |
2012-12-12 |
雅培制药有限公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
|
WO2007100098A1
(ja)
|
2006-03-03 |
2007-09-07 |
Kyoto University |
細胞表面機能分子の細胞外領域多量体
|
AU2007241023B2
(en)
|
2006-03-30 |
2013-11-28 |
University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
KR20090029184A
(ko)
|
2006-04-07 |
2009-03-20 |
더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항체 조성물 및 신생물성 질병의 치료 방법
|
AU2007281774A1
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to ErbB 2
|
UA115964C2
(uk)
|
2006-09-08 |
2018-01-25 |
Еббві Айрленд Анлімітед Компані |
Інтерлейкін-13-зв'язувальний білок
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
WO2008112193A1
(en)
|
2007-03-12 |
2008-09-18 |
Dana-Farber Cancer Institute |
Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
|
PE20081899A1
(es)
|
2007-04-02 |
2009-01-26 |
Pfizer |
Anticuerpos anti-ige
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
EP2205249B1
(en)
|
2007-09-28 |
2018-11-07 |
Intrexon Corporation |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
EP2612868B1
(en)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
CN101909693A
(zh)
|
2008-01-08 |
2010-12-08 |
百时美施贵宝公司 |
用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
KR101649189B1
(ko)
|
2008-05-09 |
2016-08-18 |
애브비 인코포레이티드 |
최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도
|
CA2725666A1
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
AU2009256250B2
(en)
|
2008-06-03 |
2013-05-30 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
NZ590074A
(en)
|
2008-07-08 |
2012-12-21 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CN102239180B
(zh)
|
2008-08-18 |
2014-12-31 |
辉瑞大药厂 |
抗ccr2抗体
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
DK3059337T3
(da)
|
2009-01-15 |
2019-07-22 |
Adaptive Biotechnologies Corp |
Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
DK2769737T3
(en)
|
2009-07-20 |
2017-07-24 |
Bristol Myers Squibb Co |
COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
|
TWI465250B
(zh)
|
2009-08-29 |
2014-12-21 |
Abbvie Inc |
治療用之dll4結合蛋白質
|
IN2012DN02737A
(sh)
|
2009-09-01 |
2015-09-11 |
Abbott Lab |
|
WO2011045704A1
(en)
|
2009-10-12 |
2011-04-21 |
Pfizer Inc. |
Cancer treatment
|
KR20140015139A
(ko)
|
2009-10-15 |
2014-02-06 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
EP2542582A4
(en)
|
2010-03-02 |
2013-12-04 |
Abbvie Inc |
THERAPEUTIC PROTEINS LINKING TO DLL4
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
EP2571532B1
(en)
|
2010-05-14 |
2017-05-03 |
Abbvie Inc. |
Il-1 binding proteins
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
CA2807014A1
(en)
|
2010-08-03 |
2012-02-09 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
RS63063B1
(sr)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S A |
Anti-ngf antitela i njihova upotreba
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US9221885B2
(en)
*
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
PL2651975T3
(pl)
|
2010-12-14 |
2018-04-30 |
Dso Nat Laboratories |
Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
RU2627171C2
(ru)
|
2010-12-21 |
2017-08-03 |
Эббви Инк. |
Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
SG10201505454SA
(en)
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
KR102004559B1
(ko)
|
2011-08-30 |
2019-07-26 |
아스텍스 파마수티컬스, 인크. |
데시타빈 유도체 제제
|
KR20140084253A
(ko)
|
2011-10-24 |
2014-07-04 |
애브비 인코포레이티드 |
Tnf에 대한 면역결합제
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
CN104271599A
(zh)
|
2011-11-08 |
2015-01-07 |
辉瑞公司 |
使用抗m-csf抗体治疗炎性疾病的方法
|
EP2791173B1
(en)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
UY34558A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
|
IL305223A
(en)
|
2012-01-27 |
2023-10-01 |
Abbvie Inc |
The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
WO2013169971A1
(en)
|
2012-05-10 |
2013-11-14 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
PL2887959T3
(pl)
*
|
2012-08-23 |
2019-04-30 |
Agensys Inc |
Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
CN110448566A
(zh)
|
2013-03-01 |
2019-11-15 |
阿斯泰克斯制药公司 |
药物组合
|
BR112015023212A2
(pt)
|
2013-03-14 |
2017-11-21 |
Gill Parkash |
tratamento do câncer utilizando anticorpos que se ligam à grp78 da superfície celular
|
BR112015023355A8
(pt)
|
2013-03-14 |
2018-01-30 |
Abbott Lab |
antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
|
EP3916103A1
(en)
|
2013-03-14 |
2021-12-01 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
KR102457731B1
(ko)
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
US11273204B2
(en)
|
2013-08-08 |
2022-03-15 |
Cytune Pharma |
IL-15 and IL-15RAPLHA sushi domain based immunocytokines
|
RS64268B1
(sr)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
PL3062815T3
(pl)
|
2013-11-01 |
2019-07-31 |
Pfizer Inc. |
Wektory do ekspresji antygenów związanych z gruczołem krokowym
|
KR20160093012A
(ko)
|
2013-11-05 |
2016-08-05 |
코그네이트 바이오서비시즈, 인코포레이티드 |
암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
|
US20160264670A1
(en)
|
2013-11-06 |
2016-09-15 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
CA2936611A1
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
SG11201610074YA
(en)
|
2014-06-06 |
2016-12-29 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CN105296433B
(zh)
*
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
CN106470697B
(zh)
|
2014-09-16 |
2019-10-25 |
兴盟生物医药(苏州)有限公司 |
抗egfr抗体以及其用途
|
KR20170072244A
(ko)
|
2014-10-10 |
2017-06-26 |
이데라 파마슈티칼즈, 인코포레이티드 |
관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
CN107074976B
(zh)
*
|
2014-11-04 |
2020-10-09 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
WO2016074580A1
(zh)
*
|
2014-11-14 |
2016-05-19 |
中国科学院上海生命科学研究院 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
KR102569813B1
(ko)
|
2014-11-21 |
2023-08-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73에 대항한 항체 및 그의 용도
|
EP3789399A1
(en)
|
2014-11-21 |
2021-03-10 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
EA201791049A1
(ru)
|
2014-12-04 |
2017-10-31 |
Бристол-Майерс Сквибб Компани |
Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
NZ734144A
(en)
|
2014-12-31 |
2023-06-30 |
Checkmate Pharmaceuticals Inc |
Combination tumor immunotherapy
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
WO2016130986A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
BR112017020404A2
(pt)
|
2015-04-07 |
2018-07-10 |
Cytlimic Inc. |
medicamento
|
PL3291679T3
(pl)
|
2015-05-06 |
2022-04-25 |
Snipr Technologies Limited |
Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
|
CA3025145A1
(en)
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
MY188049A
(en)
|
2015-05-29 |
2021-11-12 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
CA2987051A1
(en)
|
2015-05-29 |
2016-12-08 |
Abbvie Inc. |
Anti-cd40 antibodies and uses thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EA201890162A1
(ru)
|
2015-06-29 |
2018-07-31 |
Бристол-Маерс Сквибб Компани |
Антитела к cd40 с повышенной агонистической активностью
|
ES2886657T3
(es)
|
2015-06-29 |
2021-12-20 |
Bristol Myers Squibb Co |
Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
|
JP6768722B2
(ja)
|
2015-07-02 |
2020-10-14 |
大塚製薬株式会社 |
凍結乾燥医薬組成物
|
CN116059219A
(zh)
|
2015-07-16 |
2023-05-05 |
比奥克斯塞尔医疗股份有限公司 |
一种使用免疫调节治疗癌症的新颖方法
|
JP2018521983A
(ja)
|
2015-07-16 |
2018-08-09 |
バイオカイン セラピューティックス リミテッド |
がんを治療するための組成物および方法
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
WO2017079202A1
(en)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
MX2018011204A
(es)
|
2016-03-15 |
2019-03-07 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
|
AU2017234192B2
(en)
|
2016-03-16 |
2024-04-04 |
Amal Therapeutics Sa |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
JP7131773B2
(ja)
|
2016-04-29 |
2022-09-06 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
ホルモン受容体に関連する転写活性の標的尺度
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
WO2017210181A1
(en)
|
2016-05-30 |
2017-12-07 |
Geovax Inc. |
Compositions and methods for generating an immune response to hepatitis b virus
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗pd-l1およびil-2サイトカイン
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
CA3031170A1
(en)
|
2016-09-21 |
2018-03-29 |
Amal Therapeutics Sa |
Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
|
JP2020500151A
(ja)
|
2016-09-27 |
2020-01-09 |
ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム |
マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
|
BR112019006710A2
(pt)
|
2016-10-03 |
2019-06-25 |
Abbott Lab |
métodos aprimorados para avaliação do estado da uch-l1 em amostras de pacientes
|
JP6976322B2
(ja)
*
|
2016-10-10 |
2021-12-08 |
クラウン バイオサイエンス,インコーポレイテッド(タイツァン) |
新規抗ctla4抗体
|
TW201813664A
(zh)
|
2016-10-11 |
2018-04-16 |
賽多利克公司 |
醫藥
|
RU2755903C2
(ru)
|
2016-10-12 |
2021-09-22 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Способы и композиции для tusc2-иммунотерапии
|
WO2018081621A1
(en)
|
2016-10-28 |
2018-05-03 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
CN110312523B
(zh)
*
|
2016-11-08 |
2024-04-26 |
齐鲁皮吉特湾生物治疗有限公司 |
抗pd1和抗ctla4抗体
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
BR112019010878A2
(pt)
|
2016-11-29 |
2019-10-01 |
Lindhofer Horst |
combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
|
KR20190090822A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
AU2017369994A1
(en)
|
2016-12-01 |
2019-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
AU2017377233A1
(en)
|
2016-12-12 |
2019-06-13 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
WO2018156250A1
(en)
*
|
2017-02-21 |
2018-08-30 |
Remd Biotherapeutics, Inc. |
Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
|
WO2018156973A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
US20210101980A1
(en)
|
2017-03-31 |
2021-04-08 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
WO2018191531A1
(en)
|
2017-04-15 |
2018-10-18 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
JP2020517699A
(ja)
|
2017-04-26 |
2020-06-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ジスルフィド結合の還元を最小限にする抗体製造法
|
BR112019022476A2
(pt)
|
2017-04-28 |
2020-05-12 |
Abbott Laboratories |
Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
CN116478289A
(zh)
*
|
2017-05-19 |
2023-07-25 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
US11643463B2
(en)
*
|
2017-05-19 |
2023-05-09 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
|
CA3064321A1
(en)
|
2017-05-25 |
2018-11-29 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
SI3631454T1
(sl)
|
2017-05-30 |
2023-12-29 |
Bristol-Myers Squibb Company |
Zdravljenje lag-3 pozitivnih tumorjev
|
BR112019025313A2
(pt)
|
2017-05-30 |
2020-06-23 |
Abbott Laboratories |
Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
|
BR112019021847A2
(pt)
|
2017-05-30 |
2020-06-02 |
Bristol-Myers Squibb Company |
Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
EP3634584A4
(en)
|
2017-06-09 |
2021-04-07 |
Providence Health & Services - Oregon |
USE OF CD39 AND CD103 FOR THE IDENTIFICATION OF REACTIVE HUMAN TUMOR CELLS FOR THE TREATMENT OF CANCER
|
EP3649474A1
(en)
|
2017-07-03 |
2020-05-13 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
AR112336A1
(es)
|
2017-07-14 |
2019-10-16 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
BR112020000523A2
(pt)
|
2017-07-14 |
2020-07-14 |
Innate Tumor Immunity, Inc. |
moduladores de nlrp3
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
BR112020002280A2
(pt)
|
2017-08-03 |
2020-07-28 |
Otsuka Pharmaceutical Co., Ltd. |
composto farmacológico e métodos purificação do mesmo
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US11603410B2
(en)
|
2017-11-01 |
2023-03-14 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
EP3721233A2
(en)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
US11016105B2
(en)
|
2017-12-09 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
WO2019120232A1
(en)
*
|
2017-12-20 |
2019-06-27 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding ctla-4 and uses thereof
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
AU2019209435A1
(en)
|
2018-01-22 |
2020-09-17 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
AU2019236402A1
(en)
|
2018-03-12 |
2020-10-01 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
AU2019234213A1
(en)
|
2018-03-12 |
2020-09-03 |
Zoetis Services Llc |
Anti-NGF antibodies and methods thereof
|
EP3768698A4
(en)
|
2018-03-19 |
2022-03-30 |
MultiVir Inc. |
METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSIVE GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
|
WO2019179388A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel anti-ctla-4 antibody polypeptide
|
AU2019239747A1
(en)
|
2018-03-21 |
2020-10-08 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
PE20210665A1
(es)
|
2018-03-23 |
2021-03-31 |
Bristol Myers Squibb Co |
Anticuerpos contra mica y/o micb y sus usos
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
BR112020019418A2
(pt)
|
2018-03-25 |
2021-02-17 |
Snipr Biome Aps. |
tratamento e prevenção de infecções microbianas
|
EP3773551A4
(en)
|
2018-03-27 |
2022-03-23 |
Board of Regents, The University of Texas System |
COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING HER2 EXON 19 MUTATIONS
|
CN111971306A
(zh)
|
2018-03-30 |
2020-11-20 |
百时美施贵宝公司 |
***的方法
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
WO2019204592A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
KR20210005106A
(ko)
|
2018-04-25 |
2021-01-13 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
AU2019302454A1
(en)
|
2018-07-09 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to ILT4
|
BR112021000315A2
(pt)
|
2018-07-11 |
2021-08-03 |
Actym Therapeutics, Inc. |
cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
|
WO2020014327A2
(en)
|
2018-07-11 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
CA3106114A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
JP2021534180A
(ja)
|
2018-08-16 |
2021-12-09 |
イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. |
置換4−アミノ−1H−イミダゾ[4,5−c]キノリン化合物およびその製造の改良法
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
ES2930171T3
(es)
|
2018-08-16 |
2022-12-07 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-C]quinolina
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
CN113396160A
(zh)
|
2018-09-19 |
2021-09-14 |
国家医疗保健研究所 |
治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
|
TWI801664B
(zh)
|
2018-09-21 |
2023-05-11 |
大陸商信達生物製藥(蘇州)有限公司 |
新型白介素2及其用途
|
CN112105633B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
EP3860578A1
(en)
|
2018-10-01 |
2021-08-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
MX2021004059A
(es)
|
2018-10-12 |
2021-09-23 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
US20230021500A1
(en)
|
2018-10-29 |
2023-01-26 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
AU2019380307A1
(en)
|
2018-11-16 |
2021-07-01 |
Bristol-Myers Squibb Company |
Anti-NKG2A antibodies and uses thereof
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
WO2020109355A1
(en)
|
2018-11-28 |
2020-06-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kit for assaying lytic potential of immune effector cells
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
BR112021010248A2
(pt)
|
2018-11-29 |
2021-08-17 |
Board Of Regents, The University Of Texas System |
métodos para expansão ex vivo de células naturais killer e uso dos mesmos
|
EP3891270A1
(en)
|
2018-12-07 |
2021-10-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
AU2019396360A1
(en)
|
2018-12-11 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
AU2019412516A1
(en)
|
2018-12-28 |
2021-07-15 |
Transgene |
M2-defective poxvirus
|
KR20210114983A
(ko)
|
2019-01-14 |
2021-09-24 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
US20220089571A1
(en)
|
2019-01-14 |
2022-03-24 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
EP3911641A1
(en)
|
2019-01-14 |
2021-11-24 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
ES2930151T3
(es)
|
2019-01-14 |
2022-12-07 |
Innate Tumor Immunity Inc |
Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
|
AU2020208909A1
(en)
|
2019-01-15 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
KR20220007850A
(ko)
|
2019-03-13 |
2022-01-19 |
이더알엔에이 이뮤노테라피스 엔브이 |
Mrna 백신
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
CN113891748A
(zh)
|
2019-03-28 |
2022-01-04 |
百时美施贵宝公司 |
***的方法
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
EP3956446A1
(en)
|
2019-04-17 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
CA3138348A1
(en)
|
2019-05-09 |
2020-11-12 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
TW202110431A
(zh)
|
2019-05-17 |
2021-03-16 |
美商癌症預防製藥股份有限公司 |
治療家族性腺瘤性瘜肉症之方法
|
EP3976831A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
MX2021014932A
(es)
|
2019-06-03 |
2022-04-06 |
Univ Chicago |
Métodos y composiciones para tratar cáncer con portadores de fármacos que se enlazan al colágeno.
|
CN114206355A
(zh)
|
2019-06-03 |
2022-03-18 |
芝加哥大学 |
用靶向癌症的佐剂治疗癌症的方法和组合物
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
AU2020301582A1
(en)
|
2019-06-27 |
2022-02-03 |
Etherna Immunotherapies Nv |
Combination therapy
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
WO2021009188A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
BR112022000721A2
(pt)
|
2019-07-15 |
2022-03-08 |
Intervet Int Bv |
Anticorpos caninizados contra ctla-4 canina
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
JPWO2021024742A1
(sh)
*
|
2019-08-06 |
2021-02-11 |
|
|
KR20220100860A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물
|
KR20220100858A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도
|
CA3151022A1
(en)
|
2019-09-17 |
2021-03-25 |
Bial - R&D Investments, S.A. |
Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
CA3153777A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
JP2022549854A
(ja)
|
2019-09-25 |
2022-11-29 |
サーフィス オンコロジー インコーポレイテッド |
抗il-27抗体及びその使用
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
CA3157024A1
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
BR112022007632A2
(pt)
|
2019-10-25 |
2022-07-12 |
Daiichi Sankyo Co Ltd |
Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
CA3160479A1
(en)
|
2019-11-08 |
2021-05-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
TW202132297A
(zh)
|
2019-11-22 |
2021-09-01 |
美商施萬生物製藥研發Ip有限責任公司 |
經取代吡啶及使用方法
|
WO2021106978A1
(ja)
|
2019-11-27 |
2021-06-03 |
サイトリミック株式会社 |
医薬組成物
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
CN115243721A
(zh)
|
2019-12-19 |
2022-10-25 |
百时美施贵宝公司 |
Dgk抑制剂和检查点拮抗剂的组合
|
WO2021131021A1
(ja)
|
2019-12-27 |
2021-07-01 |
中外製薬株式会社 |
抗ctla-4抗体およびその使用
|
KR20220124718A
(ko)
|
2020-01-07 |
2022-09-14 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
|
WO2021142203A1
(en)
|
2020-01-10 |
2021-07-15 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル-マイヤーズ スクイブ カンパニー |
Il-10およびその使用
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
JP2023514957A
(ja)
|
2020-02-28 |
2023-04-12 |
オレガ・バイオテック |
Ctla4阻害剤及びil-17b阻害剤に基づく複合療法
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
TW202204339A
(zh)
|
2020-03-31 |
2022-02-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
經取代的嘧啶及使用方法
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
EP4136459A1
(en)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
|
CA3175499A1
(en)
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
EP4139440A1
(en)
|
2020-04-22 |
2023-03-01 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
EP4153301A2
(en)
|
2020-05-21 |
2023-03-29 |
Board of Regents, The University of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021245071A1
(en)
|
2020-06-03 |
2021-12-09 |
Mv Biotherapeutics Sa |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
TW202214623A
(zh)
|
2020-06-10 |
2022-04-16 |
美商施萬生物製藥研發 Ip有限責任公司 |
結晶型alk5抑制劑及其用途
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
US20220023405A1
(en)
|
2020-06-30 |
2022-01-27 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
KR20230035576A
(ko)
|
2020-07-07 |
2023-03-14 |
비온테크 에스이 |
Hpv 양성 암 치료용 rna
|
KR102594083B1
(ko)
|
2020-07-07 |
2023-10-25 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
JP2023534987A
(ja)
|
2020-07-24 |
2023-08-15 |
アムジエン・インコーポレーテツド |
Sars-cov2スパイクタンパク質に由来する免疫原
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
JP2023540255A
(ja)
|
2020-08-28 |
2023-09-22 |
ブリストル-マイヤーズ スクイブ カンパニー |
肝細胞癌のためのlag-3アンタゴニスト療法
|
WO2022047412A1
(en)
|
2020-08-31 |
2022-03-03 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
WO2022104109A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
MX2023006604A
(es)
|
2020-12-04 |
2023-06-19 |
Tidal Therapeutics Inc |
Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos.
|
US20240034786A1
(en)
*
|
2020-12-10 |
2024-02-01 |
WuXi Biologics Ireland Limited |
An antibody against p-cadherin and uses thereof
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
WO2022136649A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Non-blocking human ccr8 binders
|
US20240076391A1
(en)
|
2020-12-24 |
2024-03-07 |
Oncurious Nv |
Human ccr8 binders
|
WO2022146948A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
IL303648A
(en)
|
2020-12-28 |
2023-08-01 |
Bristol Myers Squibb Co |
Antibody preparations and methods of using them
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
CN117529338A
(zh)
|
2021-01-19 |
2024-02-06 |
威廉马歇莱思大学 |
多肽的骨特异性递送
|
CA3203705A1
(en)
|
2021-01-22 |
2022-07-28 |
Erik Hans MANTING |
Methods of tumor vaccination
|
AU2022235341A1
(en)
|
2021-03-12 |
2023-09-21 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
EP4079311A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
US20220381796A1
(en)
|
2021-05-18 |
2022-12-01 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
EP4356129A1
(en)
|
2021-06-14 |
2024-04-24 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
KR20240024255A
(ko)
|
2021-06-25 |
2024-02-23 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체의 사용
|
CR20240026A
(es)
|
2021-06-25 |
2024-03-14 |
Chugai Seiyaku Kk |
Anticuerpo anti-ctla-4
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
KR20240046323A
(ko)
|
2021-07-13 |
2024-04-08 |
비온테크 에스이 |
암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
IL310550A
(en)
|
2021-08-04 |
2024-03-01 |
Univ Colorado Regents |
LAT-activating chimeric antigen receptor T cells and methods of using them
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3234457A1
(en)
|
2021-10-05 |
2023-04-13 |
Cytovia Therapeutics, Llc |
Natural killer cells and methods of use thereof
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
WO2023097024A1
(en)
*
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商eTheRNA免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240156A1
(en)
|
2022-06-08 |
2023-12-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|